Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-08-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Cellid' (제 20 기, 2025년 01월 01일 ~ 2025년 06월 30일). It contains detailed financial information, business operations, management discussions, and corporate governance details for the first half of the fiscal year. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim/Quarterly Report (IR). H1 2025
2025-08-14 Korean
소송등의판결ㆍ결정(일정금액이상의청구)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure regarding a court ruling on a lawsuit ('소송등의판결ㆍ결정'). It details the case name, parties involved, the court's decision (dismissal of the injunction), and the date of the ruling. This falls under the category of legal proceedings and regulatory disclosures regarding litigation.
2025-08-12 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Stock Option Grant). It details specific changes to previously reported stock option grants, including adjustments to the number of shares, exercise prices, and beneficiary details. This type of filing is a standard regulatory disclosure regarding capital structure and equity compensation, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for new capital issuance).
2025-06-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Granting Stock Options). It details adjustments to the number of shares and exercise prices for previously granted stock options. In the context of financial filings, reports regarding stock option grants, amendments, or capital structure changes that do not fit into specific categories like 'Director's Dealing' or 'Share Issue' are classified as Regulatory Filings (RNS) as they are official disclosures submitted to the financial authorities (Financial Services Commission/Korea Exchange).
2025-06-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고 정정신고' (Amendment to the Report on Stock Option Grant). It details specific changes to previously reported stock option data, such as the number of shares granted, exercise prices, and the list of recipients. This falls under the category of regulatory filings related to capital structure and equity compensation, which is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like Director's Dealing or Share Issue/Capital Change.
2025-06-30 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report) for a previously submitted stock option grant. It details changes to the number of shares, exercise price, and total status of stock options granted to employees. This type of disclosure regarding capital structure changes and employee stock options falls under the category of regulatory filings for corporate actions that do not fit into specific financial reporting categories like 10-K or ER.
2025-06-30 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.